CoChat

Lapatinib Distribution in HER2 Overexpressing Experimental Brain Metastases of Breast Cancer

Open access
Taskar, Kunal S., Rudraraju, Vinay, Mittapalli, Rajendar K., Samala, Ramakrishna, Thorsheim, Helen R., Lockman, Julie, Gril, Brunilde, Hua, Emily, Palmieri, Diane, Polli, Joseph W., Castellino, Stephen, Rubin, Stephen D., Lockman, Paul R., Steeg, Patricia S., Smith, Quentin R. · 2012 · Pharmaceutical Research
Cited by 202

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Lapatinib, a small molecule EGFR/HER2 inhibitor, partially inhibits the outgrowth of HER2+ brain metastases in preclinical models and in a subset of CNS lesions in clinical trials of HER2+ breast cancer. We investigated the ability of lapatinib to reach therapeutic concentrations in the CNS following 14C-lapatinib administration (100 mg/kg p.o. or 10 mg/kg, i.v.) to mice with MDA-MD-231-BR-HER2 brain metastases of breast cancer. Drug concentrations were determined at differing times after administration by quantitative autoradiography and chromatography. 14C-Lapatinib concentration varied among brain metastases and correlated with altered blood-tumor barrier permeability. On average, brain metastasis concentration was 7–9-fold greater than surrounding brain tissue at 2 and 12 h after oral administration. However, average lapatinib concentration in brain metastases was still only 10–20% of those in peripheral metastases. Only in a subset of brain lesions (17%) did lapatinib concentration approach that of systemic metastases. No evidence was found of lapatinib resistance in tumor cells cultured ex vivo from treated brains. Results show that lapatinib distribution to brain metastases of breast cancer is partially restricted and blood-tumor barrier permeability is a key component of lapatinib therapeutic efficacy which varies between tumors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s11095-011-0601-8

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 202

Metadata

Authors
Taskar, K. S., Rudraraju, V., Mittapalli, R. K., Samala, R., Thorsheim, H. R., Lockman, J., Gril, B., Hua, E., Palmieri, D., Polli, J. W., Castellino, S., Rubin, S. D., Lockman, P. R., Steeg, P. S., & Smith, Q. R.
Venue
Pharmaceutical Research
Published
2011-10-20
Volume
29
Issue
3
Pages
770-781
ISSN
  • 0724-8741 (ISSN-L)
  • 1573-904X
OpenAlex
W2131558896
Cited by
202
References
5
FWCI
8.13
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Lapatinib Distribution in HER2 Overexpressing Experimental Brain Metastases of Breast Cancer. https://app.cochat.ai/papers/10.1007/s11095-011-0601-8
The paper
Taskar, K. S., Rudraraju, V., Mittapalli, R. K., Samala, R., Thorsheim, H. R., Lockman, J., Gril, B., Hua, E., Palmieri, D., Polli, J. W., Castellino, S., Rubin, S. D., Lockman, P. R., Steeg, P. S., & Smith, Q. R. (2012). Lapatinib Distribution in HER2 Overexpressing Experimental Brain Metastases of Breast Cancer. Pharmaceutical Research. https://doi.org/10.1007/s11095-011-0601-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.